Multinational Pharma Giants Accelerate China Strategies with Capacity Expansion, R&D Reinforcement, and Strategic Partnerships

　　【Pharmaceutical Network Industry Dynamics】Currently, China has become the world's largest pharmaceutical market and an important strategic market for most global pharmaceutical companies. It is reported that in 2023, the strategic layout of many multinational pharmaceutical companies in China will enter a new stage.
 

It is reported that since this year, many multinational pharmaceutical companies have landed new plants in China, expanded production capacity, and increased investment. For instance, Novartis announced at the beginning of December this year that it would invest in establishing a brand-new radiopharmaceutical production base in China to accelerate the introduction of innovative radioligand therapies into China. The total investment in this production base is expected to exceed 600 million RMB. Provided that the relevant drugs receive regulatory approval, production is expected to commence by the end of 2026.
 

In November this year, Moderna's first pharmaceutical factory in China, the "Moderna China R&D and Manufacturing Headquarters Project," commenced construction. The project covers an industrial land area of nearly 270 mu, with a total investment of approximately 3.6 billion yuan. Merck announced the official launch of its first biosafety testing laboratory facility in China, providing services such as cell bank characterization and batch release testing required from preclinical development to commercial market launch.
 

In addition, on June 8, Sanofi officially launched the localization project for its innovative compound hypoglycemic drug Soliqua®. The launch of this project marks the formal localization of Soliqua® production at the Beijing production base. Sanofi stated that the total investment in this localization project is nearly 500 million RMB, with plans to build a new aseptic...Filling Production Line, and upgrade the existing assembly production line to continuously expand the manufacturing capacity of insulin products, further increasing local production capacity in China.
 

In February this year, the groundbreaking ceremony for the expansion project of the finished product workshop at Novo Nordisk's Tianjin production plant was held. The upcoming construction of the finished product workshop and the pre-filled injection pen production line introduction project is expected to involve a total investment of approximately 1.18 billion yuan, covering an area of 4,218.88 square meters with a building area of 13,110 square meters. This marks another milestone in Novo Nordisk’s development in Tianjin, following the approximately 500 million yuan investment in the high-rise automated warehouse project in the fourth quarter of 2022.
 

In addition to expanding production capacity, some multinational pharmaceutical companies have directly increased their R&D investment in China. For instance, Boehringer Ingelheim revealed plans to invest over 4 billion yuan in R&D in China within the next five years. AstraZeneca’s Shanghai R&D platform has been upgraded to become the company's Global R&D China Center, with more than 180 pipeline projects currently under development in China. It is estimated that within the next five years, AstraZeneca will receive approval for approximately 80 new drugs and indications in China.
 

At the same time, an increasing number of multinational pharmaceutical companies are collaborating with Chinese pharmaceutical enterprises. For instance, Sanofi China and Shanghai Pharmaceutical Co., Ltd. announced on December 15 the official signing of a strategic cooperation agreement to engage in extensive and in-depth collaboration across all channels and throughout China in key disease areas, establishing an end-to-end value chain system from import, distribution to terminal sales.
 

HUTCHMED Subsidiary Hutchison MediPharma Partners with Takeda Pharmaceutical Company Limited. Takeda Obtains International Development, Commercialization, and Manufacturing Rights for Hutchison MediPharma’s Product Fruquintinib, While Hutchison MediPharma Can Earn Up to $1.13 Billion from the Deal.
 

Roche Diagnostics China and Beijing Strong Biotechnologies, Inc. (BSBE) announced that they will further expand and deepen their cooperation. It is reported that as early as 2016, Roche Diagnostics and BSBE had signed a cooperation agreement based on biochemical reagents. This time, Roche Diagnostics and BSBE will join hands again to focus on the localized needs of the Chinese market, concentrating on the coagulation field, and have cooperatively developed Fibrin(ogen) Degradation Products (FDP) testing, among others.
 

Analysts pointed out that, with the in-depth advancement and popularization of the Healthy China initiative, China's health care sector has achieved remarkable results, and the pharmaceutical market scale continues to expand. This also brings numerous opportunities for multinational pharmaceutical companies to establish a presence in the Chinese market. Data predicts that by 2030, the scale of China's pharmaceutical market is expected to exceed 2.7 trillion yuan. Facing the enormous opportunities in the Chinese market, increasing investment in the Chinese market has become a common choice for multinational pharmaceutical enterprises.
 

Disclaimer: In no case shall the information or opinions expressed in this article constitute investment advice to any person.